SHANGHAI, March 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2022 Annual Results.

Business Highlights

• Zevor-cel (CT053) NDA was accepted by the NMPA (Oct 2022) with priority...